Cefotetan is a new, potent, 7a-methoxy cephalosporin (cephamycin). The in vitro activity of cefotetan tested in a multiphasic, collaborative study against 12,260 consecutive clinical isolates and 448 selected isolates showed 93% of Enterobacteriaceae, 90% of methicillin-susceptible Staphylococcus aureus (broth dilution), 83% of Bacteroides fragilis, and 72% of non-enterococcal streptococci to be inhibited by s8 ,ug/ml. ,B-Lactamase-producing and -nonproducing Haemophilus influenzae strains were inhibited by s1.0 ,ug/ml. Cefotetan's inhibitory spectrum paralleled those of the newest generation of cephems and exceeded those of cefoxitin and cefamandole. No useful activity was present against Streptococcus faecalis or Pseudomonas aeruginosa. Cefotetan was bactericidal without significant inoculum effect and was highly resistant to hydrolysis by Richmond-Sykes types I, III, and IV P-lactamases. Hydrolysis of the chromogenic cephalosporin PADAC (pyridine-2-azo-p-dimethylaniline cephalosporin) by type I ,B-lactamases was markedly inhibited by concentrations of cefotetan similar to those of the potent inhibitor dicloxacillin. Analysis of agar disk diffusion for several disk potencies and broth dilution susceptibility tests by regression and error rate-bounding methods produced preliminary tentative zone standards (30-,ug disk, using minimal inhibitory concentration breakpoints of <8 p.g/ml susceptible and >32 ,ug/ml resistant, or 75-,ug disk, using minimal inhibitory concentration breakpoints of <16 ,ug/ml susceptible and -64 ,ug/ml resistant) of .18 mm susceptible, s14 mm resistant, and 15 to 17 mm indeterminate. Staphylococcus aureus testing with the 30-,ug disk is not recommended.
Cefotetan, 7p-[4-(carbamoylcarboxylatomethylene)-1 ,3-dithietan-2-yl]carboxamido-7a-methoxy-3-(1 -methyltetrazol -5 -yl)thiomethyl-A3-cephem-4-carboxylic acid, is a new semisynthetic cephamycin with the unusual feature of tautomeric changes to produce small amounts of a tautomer with similar antimicrobial activity (6) . Cefotetan (disodium derivative YM09330), like the other methoxy ,-lactams cefoxitin and moxalactam ( Fig. 1 ), has been reported to have extensive resistance to hydrolysis by the Plactamases of gram-negative bacteria, to display broad-spectrum antibacterial activities, and to have favorable pharmacokinetic properties (14, 23, (25) (26) (27) . To define and compare the in vitro antimicrobial activities of cefotetan (acid), a multiphasic, collaborative study was undertaken at seven clinical microbiology laboratories located in six geographically distinct regions of the United States. This report describes the following: (i) minimal inhibitory concentrations (MICs) of cefotetan compared with those of cefoxitin and cefamandole against 12,260 consecutive clinical bacterial isolates from clinical microbiology laboratories; (ii) comparison of the MICs of cefotetan with those of a panel of broad-spectrum antimicrobials against a selected bacterial population of aerobic, fastidious, and anaerobic species; (iii) comparison of cefotetan and cefoxitin for the effects of inoculum density on antimi- MATERIALS AND METHODS Antibiotics. Cefotetan (acid) was supplied as a standard powder to the investigative group by Stuart Pharmaceuticals (Division of ICI Americas, Inc.), Wilmington, Del. Other antimicrobial agents were secured by individual investigators and included: cefoxitin (Merck Sharp & Dohme, West Point, Pa.); cefazolin, cefamandole, and moxalactam (Eli Lilly Research Laboratories, Indianapolis, Ind.); ampicillin, dicloxacillin, and ceforanide (Bristol Laboratories, Syracuse, N.Y.); carbenicillin and cefoperazone (Pfizer Inc., New York, N.Y.); ceftriaxone (Hoffmann-LaRoche Inc., Nutley, N.J.); cefotaxime, cefodizime, and pyridine-2-azo-p-dimethylaniline cephalosporin (PADAC; Hoechst-Roussel Pharmaceuticals Inc., Somerville, N.J.); chloramphenicol (Parke, Davis & Co., Detroit, Mich.); clindamycin (The Upjohn Co., Kalamazoo, Mich.); metronidazole (G.D. Searle & Co., Chicago, Ill.); clavulanic acid (Beecham Pharmaceuticals, Bristol, Tenn.); and nitrocefin (Glaxo, Inc., Ft. Lauderdale, Fla.). Cefotetan disks (10, 30, and 75 ,ug) were prepared by hand from standard powders as single lots in the laboratory of the University of California, Davis, Medical Center and then distributed to participating investigators. Cefoxitin disks, 30 i&g, were commercially prepared (Difco Laboratories, Detroit, Mich.).
Organsms. Consecutive Tables 1 to 3. Selected bacteria for special comparison studies came from some of the above sources as well as the Kaiser Foundation Hospital, Clackamas, Ore.; St. Vincent Hospital and Medical Center, Portland, Ore.; and the Centers for Disease Control (CDC), Atlanta, Ga. This organism group was assembled to reflect the composition of clinically significant populations and included the same strains as had been used in earlier studies of similar new 1-lactams (7) (8) (9) (10) (11) . Groups were constituted as indicated in Tables 5 to 8 (12), P. fluorescens-putida (8), P. putrefaciens (1), P. stutzeri (18) , P. acidovorans (3), P. alcaligenes (6), P. paucimobilis (1), P. testosteroni (5) and Pseudomonas sp. NOS (2) .
c Includes (number of isolates): Achromobacter xylosoxidans (9), Alcaligenes spp. (14) , CDC group Il-F (1), CDC group ID-2 (1), CDC group VE-I (1), CDC group IV-E (1), Eikenella corrodens (3), Flavobacterium spp.
(8), Haemophilus influenzae (5) , Moraxella osloensis (2), and Pasteurella multocida (3). Proteus mirabilis, 15), 140 staphylococci (Staphylococcus aureus, 120; Staphylococcus epidermidis, 20), 1 Acinetobacter spp., 1 Pseudomonas aeruginosa, 2 P. stutzeri, and 1 Streptococcus bovis were assembled. For study of inoculum effect and bactericidal activity, 110 strains of common genera were assembled; included were (number of isolates): Citrobacter diversus (5), Citrobacter freundii (5), Enterobacter aerogenes (5), Enterobacter cloacae (5), Escherichia coli (10), Klebsiella pneumoniae (10), Proteus mirabilis (10), Proteus spp., indole-positive group (7 Morganella morganii, 7 Providencia rettgeri, and 6 Proteus vulgaris), Serratia marcescens (10), Pseudomonas aeruginosa (10), Staphylococcus aure-us (10), and Streptococcus faecalis (10) . Ten reference strains and a commercially produced penicillinase (BBL Microbiology Systems, Cockeysville, Md.; Bacillus cereus) were utilized for 3-lactamase studies (Tables 9 and 10) (4, 18, 23) . Bacteria listed in Tables S to 7, excluding the pathogenic Neisseria sp., were used to study disk zone diameters. The numbers of observations are reported in Table 12 . Five strains recommended for control of MIC or disk procedures were also tested and are listed in Table 13 .
Antimicrobial susceptibility testing. With the consecutive clinical isolates, MICs of cefotetan were determined at the Cleveland Clinic Foundation, University of California, Davis, Medical Center, and University a For all three antimicrobial agents, strains inhibited by 8.0 ,ug/ml or less are considered susceptible. All results are rounded to nearest whole number.
Hospitals by a microtube broth dilution method as previously described (2, 7, 9, 10, 17) and at Northwestern Memorial Hospital and St. Francis Hospital by the reference agar dilution method recommended by the National Committee for Clinical Laboratory Standards (17) . Test panels and agar plates were prepared by the individual investigators to provide antibiotic concentrations of 0.125, 0.5, 1.0, 2.0, 4.0, 8.0, and 32 gLg/ml. The bacterial inoculum for the microtube broth test was approximately 10' colony-forming units/ml, and that for the agar dilution method was approximately 104 colony-forming units per spot inoculation. MICs and minimum bactericidal concentrations for the selected bacterial populations were also determined by the microtube broth dilution method. Special test panels were prepared as individual production lots by a commercial manufacturer (Prepared Media Laboratories, Portland, Ore.). Drug concentrations were prepared appropriate to the antimicrobial agent in twofold dilution steps ranging from 0.008 to 256 ,ug/ml (Tables 5 to 8 ). Test panels were frozen at -70°C and then shipped to selected investigators. Determination of MICs to demonstrate the effects of inoculum density on susceptibility and determination of minimum bactericidal concentrations were performed by previously described methods (9, 10) . The inocula for the inoculum density effect were 103, 105, and 107. MIC50s and MIC90s were calculated for all genera or organism group of genera. The bactericidal activity was calculated as that concentration of cefotetan and cefoxitin inhibiting 90o (MIC90) of strains within each of the genera or groups, and the geometric mean of MIC/minimum bactericidal concentration was calculated.
The fastidious microbes were tested at CDC by using a microtube antimicrobial test plate filled with Mueller-Hinton broth supplemented with 5% Fildes solution (Haemophilus influenzae, Neisseria meningitidis, beta-hemolytic streptococci, and Streptococcus pneumoniae) and by a modified agar dilution method with proteose peptone agar no. 3 supplemented with 1% hemoglobin and 1% Kellogg supplement (Neisseria gonorrhoeae). Both of these modified dilution tests have been reported earlier (1, 25) . Anaerobic isolates were tested by using Wilkins-Chalgren agar according to the reference agar dilution method (National Committee for Clinical Laboratory Standards) with incubation at 35°C for 48 h in GasPak (BBL Microbiology Systems) jars (11, 13, 22) . Appropriate control organisms were run with all tests.
3-Lactamase hydrolysis rates of cefotetan and comparison antimicrobial agents were performed with crude 13-lactamases prepared from the known typeproducing strains according to methods described by Fu and Neu (5, 18) . The test reactions were referenced to relative hydrolysis of nitrocefin or cephaloridine or both and were monitored with a scanning UV spectrophotometer over the range of 260 to 482 nm at 37°C (20) . Inhibitions of the crude ,-lactamases by cefotetan and comparison antimicrobial agents were determined by adding various concentrations of test inhibitors (0.1, 1.0, 10, and 100 FM) and enzyme preparation to the enzyme-labile substrate PADAC (0.5 x 10-4 M) (12, 19, 21) . This reaction mixture at 37°C was followed by using a centrifugal-fast analyzer (Centrifi-Chem 400; Union Carbide, Tarrytown, N.Y.) monitored at ca. 550 nm (12) .
Disk diffusion tests were performed in parallel with the MICs on the selected organism population using the agar disk technique as outlined by the National Committee for Clinical Laboratory Standards (16) . Results from the cefotetan and cefoxitin disk tests and the broth dilution MICs were compared by both regression analyses, according to the formula of least squares adapted for computer computation, and the error rate-bounded method of Metzler and DeHaan (15) . Cross-resistance analyses comparing cefotetan and cefoxitin were also performed.
RESULTS
Activities of cefotetan, cefoxitin, and cefamandole. The in vitro activity of cefotetan compared with those of cefoxitin and cefamandole against consecutive clinical bacterial isolates are given in Tables 1, 2 , and 3. For all species tested, cefotetan was more active than cefoxitin, and except for its greater activity against Enterobacter spp., cefamandole was less active than cefotetan for all enteric bacteria tested. Only strains of Citrobacterfreundii, Enterobacter aerogenes, and Enterobacter cloacae demonstrated a high level (>32 jig/ml) of resistance to cefotetan.
Resistant strains of these species were reported from all of the clinical laboratories participating in this phase of the study. Cefamandole was more active than cefotetan against Staphylococcus aureus, Staphylococcus epidermidis, and the hemolytic streptococci; neither cefotetan nor the comparison antibiotics displayed significant activity against the enterococci. Nonenteric gram-negative bacilli demonstrated species-specific susceptibility patterns ( Table 3 ). The consecutive clinical isolates are summarized in Table 4 .
Activity of cefotetan and selected antibiotics.
The in vitro activities of cefotetan compared with eight selected "first-," "second-," and "third"-generation P-lactams against selected isolates of Enterobacteriaceae are given in Table 5 . Cefotetan, like most of the comparison ,Blactams, had little activity against Acinetobacter calcoaceticus subsp. antitratus (Table 6 ). Cefotetan and cefoxitin showed good inhibition of both ampicillin-susceptible and ampicillin-resistant strains of Haemophilus influenzae. Cefamandole was twice as active as cefotetan against ampicillin-susceptible strains but showed a significant loss of activity against ampicillin-resistant strains. Cefotetan was appreciably less active on a weight basis against H. influenzae when compared with cefodizime, cefoperazone, ceftriaxone, and moxalactam. Penicillin-susceptible and -resistant strains of Neisseria gonorrhoeae were susceptible to all of the newer Ilactams tested. Pseudomonas aeruginosa and other Pseudomonas species were generally resistant to cefotetan and variably susceptible to the comparison antimicrobial agents. (12) Providencia rettgeri (12) Providencia stuartii (24) Serratia marcescens (29) . The MIC9os of the P-lactams against selected gram-positive species (Table 7) were generally higher for the third-generation agents than for the older agents. The MIC90 of 8.0 F.g/ml for Staphylococcus aureus within this selected population was lower than the MIC9o of 32 p.g/ml listed for the consecutive clinical isolates of this species. An explanation for this difference was provided in the results of the comparison of the 250 selected clinical isolates tested for MICs by both the reference agar dilution and the refer- a Includes one 13-lactamase-negative, ampicillin-resistant isolate and two strains resistant to chloramphenicol. b Includes five 1-lactamase-negative strains with ampicillin MICs of 0.5 to 4.0 ,ug/ml. I Includes strains from six species with cefotetan susceptibility rank order as follows (MIC50 for each species in parentheses): Pseudomonas stutzeri (1.0 ,ug/ml) > P. acidovorans (2.0 ,g/ml) > P. cepacia (32 ,g/ml) = P. maltophilia (32 ,Lg/ml) > P. putida (64 ,g/ml) > P. fluorescens (256 jig/ml).
There was diminished inhibitory activity for all tested P-lactams against the methicillin-resistant strains of Staphylococcus aureus.
When tested against a variety of anaerobic isolates in comparison with antibiotics known to be active against anaerobes, cefotetan demonstrated variable activity (Table 8) . Cefotetan compared well with cefoxitin, and these cephamycins were more active than cefamandole against anaerobes taken as a group. None of the ,B-lactams tested, cefotetan, cefoxitin, cefamandole, or carbenicillin, was as consistently inhibitory as clindamycin, metronidazole, or chloram-phenicol. Among the Bacteroidesfragilis group, cefotetan was more active against Bacteroides fragilis strains (83% with MICs of s8.0 ,ug/ml) than against Bacteroides distasonis or Bacteroides thetaiotaomicron strains. Because of these latter species, the Bacteroides fragilis group demonstrated an MIC90 of >32 ,ug/ml. Effect of inoculum density and bactericidal activity. The effect of inoculum densities of 103 105, and 07 on MICs of cefotetan compared with cefoxitin was tested on 110 isolates from clinical infections. The MIC90s were essentially the same for all inocula (within one log2 dilution) VOL. 22, 1982 the cefotetan MIC9o between inocula of 103 to 1(7 and a similar fourfold rise for cefoxitin; the inoculum effect was not attributed to any specif-ic organism-drug interaction. The inhibitory and bactericidal concentrations of cefotetan affecting 90% of the isolates were essentially the same: a comparison of the ratio of geometric means for these concentrations revealed that only three of the eight genera tested had a value greater than 1; all were less than 2 (range, 0.89 to 1.84).
P-Lactamase stability of cefotetan. As expected from the 7a-methoxy configuration of cefotetan, the gram-negative 3-lactamases tested demonstrated little hydrolytic activity ( Table 9 ). Enzyme types I, Ia, IlIa, IlIb, IV, and IVc produced very low relative hydrolysis rates compared with cephaloridine. Cefoxitin, moxalactam, and cefotaxime, by comparison, showed similar resistances to enzymatic hydrolysis but did demonstrate individual patterns of minor hydrolysis by enzyme types II, IlIa, IV, and IVc. All of the antimicrobial agents showed some level of hydrolysis by enzyme type II (Pseudomonas aeruginosa), with moxalactam, cefazolin, and cefotetan being most susceptible. Inhibition of 3-lactamases by cefotetan. The addition of cefotetan to enzyme preparations containing a labile chromogenic substrate, PADAC, inhibited hydrolysis of this chromogen by enzyme types I and Ia (Table 10) . Similar hydrolysis inhibition was demonstrated by cefoxitin, moxalactam, and cefotaxime, with moxalactam also inhibiting the action of enzyme type "new." The 7a-methoxy cephems demonstrated the same high-efficiency, low-percent inhibitor concentration seen with dicloxacillin for enzyme type Ia (Fig. 2) . This low-percent concentration response curve demonstrated the similarity in the inhibitory activities of dicloxacillin and the 7a-methoxy cephems when compared with another cephem, cefoperazone, which required a high inhibitor percent concentration to produce similar levels of enzyme inhibition. Both low and high levels of enzyme inhibition differentiated these cephems from compounds such as clavulanic acid, which displayed no inhibition of the type Ia ,B-lactamase.
Activity of cefotetan against multiresistant bacteria. The in vitro activity of cefotetan was compared with those of selected antimicrobial agents against two populations of multi-drugresistant bacteria (Table 11 ). The cephalothincefamandole-resistant group was composed of isolates of Enterobacteriaceae adjusted to the frequency encountered in the consecutive clinical isolates. Cefotetan inhibited a larger percentage of strains at <8.0 ,ug/ml (61%) than did either cefoxitin (35%) or ceforanide (16%) and was essentially equal in activity to cefoperazone (64%) at that concentration. Ceftriaxone and moxalactam were more active, with 90 and 93% of strains, respectively, inhibited at <8.0 ,ug/ml. The aminoglycoside-resistant group was composed largely of Pseudomonas species and Staphylococcus aureus. Cefotetan was more inhibitory at 8.0 ,ug/ml (58%) than were cefoxitin (38%), cefamandole (46%), and ceforanide (40%). Cefoperazone was significantly more active at the same concentration, with 81% of strains inhibited. At a concentration of s16 pRg/ml, cefoperazone was most active (87%), but moxalactam (85%), ceftriaxone (79%), and cefotetan (63%) inhibited a significant portion of this resistant population. The composition of this resistant group favored the performance of cefoperazone (10) .
Antimicrobial disk tests. Regression line statistics utilizing the method of least squares was developed for 10-, 30-, and 75-,ug cefotetan and 30-,ug cefoxitin disks. For each cefotetan disk potency, four regression range analyses were developed, each excluding a portion of the extremely susceptible and resistant strains to finally include only data near the MIC breakpoints. Cefoxitin data were similarly evaluated, and in all instances the correlation coefficient, slope, and Y-axis intercept were recorded (Table 12 ). The regression curves, including all data for cefotetan, were parabolic, distorted by the large cluster of very susceptible strains with MICs of -2.0 ,ug/ml. The exclusion of these strains produced regression lines with more accurate slopes. The slope of the 75-,ug disk closely resembled the slope produced by the control disk cefoxitin. The 10-,ug disk was not considered further because of the flatness of the slope (-0.15) and the low Y intercept (28 ,ug/ml) obtained with the restricted MIC data.
Because the regression lines for the antimicrobial disk zone and MIC data were distorted, the error rate-bounded method (15) for antimicrobial zone analysis was applied. A scattergram for the cefotetan 30-p,g disk zone diameters and corresponding MICs was developed (Fig. 3 ). Tentative zone standards with MIC breakpoints of -8.0 ,ug/ml (susceptible) and >32 ,ug/ml (resistance) were <14 mm (resistant) and .18 mm (susceptible). Using this interpretation, one (0.2%) very major error (false susceptible), one (0.2%) major error (false resistance), and 8.1% minor errors occurred. The large number of minor errors related to the choice of an MIC breakpoint (8.0 ,ug/ml), which did not fall at a natural break between organism clusters. The MIC population distribution of the consecutive clinical isolates (Fig. 4 ) demonstrated three major organism clusters: <0.12 to 1.0 ,ug/ml (Enterobacteriaceae), 2.0 to 8.0 ,ug/ml (methicillinsusceptible Staphylococcus aureus) and .32 ,ug/ml (pseudomonads, methicillin-resistant Staphylococcus aureus, and enterococci). As the Staphylococcus aureus population was tran-VOL. 22, 1982 Few organisms fell into the 16to 32-,ug/ml range and consisted mostly of Enterobacter spp., Acinetobacter spp., Pseudomonas spp., and a few methicillin-resistant Staphylococcus aureus isolates. Development of tentative zone standards for the 30-,ug disk with MIC breakpoints of <16 ,ug/ml (susceptible) and .64 jig/ml (resistant) gave zone sizes too small to expect reproducible results (16) .
A similar scattergram for the 75-,ug disk ( Fig.  5 ), using MIC breakpoints of -16 ,ug/ml (susceptible) and .64 ,ug/ml (resistant), resulted in tentative zone standards of -14 mm (resistant) and .18 mm (susceptible). Improved rates with no very major errors, one (0.2%) major error, and 3.6% minor errors resulted. b Per milliliter of partially purified P-lactamase preparation. c RHR, Relative hydrolysis rate; compared with that of cephaloridine ,-lactamase expressed as a value of 100%. The ,-lactamase hydrolysis was determined by the UV spectrophotometric method, using 265 to 482 nm at 37°C. Reaction mixtures were at a volume of 1.0 ml of 10-4 M cephalosporin substrate in 0.05 M phosphate buffer, pH 7. d NT, Not typed (commercial penicillinase from Bacillus cereus).
VOL. 22, 1982 Additional advantage for the l16-,zg/ml breakpoint was demonstrated by the results of the quality control strains (Table 13 ). The disk zone ranges for Escherichia coli ATCC 25933 (modal MIC, 0.12 SLg/ml) fell within the appropriate range for any of the tentative zone standards examined, as did those for Pseudomonas aeruginosa ATCC 27853 (modal MIC, 256 ,ug/ml). For Staphylococcus aureus ATCC 25923 (modal MIC, 8 The results of computer-generated linear regression plots and scattergrams comparing cefotetan and cefoxitin in MIC versus MIC plots, zone diameter versus zone diameter plots, and cefoxitin-MIC versus cefotetan-zone diameter plots showed poor correlations of susceptibilityresistance, indicating that the results from the cefoxitin disk or MICs would be inappropriate to define the susceptibility of cefotetan and vice versa.
DISCUSSION
This extensive evaluation of the performance of cefotetan (acid), a potent new cephamycin, against a large and geographically diverse population of clinical bacterial isolates demonstrates results similar to those reported (26-28) for the cefotetan disodium derivative YM09330.
The antimicrobial activities of this 1-lactam reflect both the increase in intrinsic activity and the resistance to destruction by bacterial ,Blactamases which have become the hallmark of third-generation cephems. Cefotetan demonstrates increased intrinsic activity against most of the species ofEnterobacteriaceae tested compared with cefoxitin, cefamandole, and older agents such as cefazolin and has activities at MIC90s approximating those of the new 3-lac- (-------) ,ug/ml. tams cefodizime, ceftriaxone, and moxalactam. Excellent resistance to the action of bacterial P-lactamases due to the 7a-methoxy moiety accounts for some of the improved activity over the more enzyme-susceptible agents cefazolin and cefamandole. With nonenteric gram-negative organisms, cefotetan demonstrates little increase in intrinsic activity over cefoxitin. The activity of cefotetan against Bacteroides fragilis is less than might have been expected after studies which have shown excellent bactericidal action against susceptible strains and a high resistance to hydrolysis by P-lactamases from strains of Bacteroides fragilis (K. Ueno, K. Watanabe, and M. Isono, Program Abstr. Intersci. Conf. Antimicrob. Agents Chemother. 21st, Chicago, Ill., abstr. no. 121, 1981). Activity against resistant Bacteroides strains is not potentiated by clavulanic acid, suggesting the oc-currence of resistance mechanisms other thanlactamase hydrolysis (28) .
Cefotetan closely resembles moxalactam in its activity against gram-positive species; both cephems demonstrate less intrinsic activity against this organism group than all other agents tested (Tables 2, 4, and 7). Of particular interest is the modest activity against Staphylococcus aureus, with MIC90s of 8.0 to 32 ,ug/ml (cefotetan) and 16 ,ug/ml (moxalactam). These MICs, however, can be exceeded by the high serum levels reported for both antimicrobial agents (3, 24) .
Cefotetan susceptibility testing is reproducibly performed with either the standard agar disk diffusion or the microtube broth dilution test (16, 17) . A tentative susceptible breakpoint of <16 ,g/ml and a resistant breakpoint of -64 ,ug/ml, using a 75-Rg disk, is recommended if Staphylococcus aureus is to be tested. This choice of breakpoints is supported by the natural MIC clusters formed by a large clinical isolate population ( Fig. 4 ) and the reported high and prolonged serum levels of the disodium derivative exceeding those of moxalactam (M. Shinohara, I. Nakayama, A. Saito, and K. Mashimo, Program Abstr. Int. Congr. Chemother. 12th, Florence, Italy, abstr. no. 183, 1981) .
If the susceptible MIC should prove to be c8.0 ,ug/ml, not <16 ,ug/ml, the 30-,ug disk test could readily separate resistant and susceptible populations if Staphylococcus aureus is not tested.
Because the disks used in this study were handmade, the zone size recommendations must be considered tentative. The regression analysis of MIC and disk zones must be repeated when commercial disks become available. Preliminary quality control data (Table 13) show good precision for both agar disk and broth dilution methods of susceptibility testing and should serve as a guide until definitive tests and quality control In conclusion, in vitro testing of large numbers of consecutive and selected clinical isolates demonstrates the excellent intrinsic activity of cefotetan against commonly isolated Enterobacteriaceae species and achievable levels of activity against a wide variety of bacteria exclusive of all strains of Pseudomonas aeruginosa, enterococci, and methicillin-resistant Staphylococcus aureus. Additional desirable in vitro characteristics of bactericidal action, absence of inoculum effect, broad resistance to P-lactamase hydrolysis, potent inhibition of type I 1-lactamases, and reproducible susceptibility tests contribute to a favorable evaluation of this antimicrobial agent. Interest in further study should be stimulated.
